Johnson & Johnson’s Ketamine Nasal Spray Becomes $1.7 B Blockbuster Amid Regulatory Hurdles

Johnson & Johnson’s Spravato, a nasal spray derived from the anesthetic ketamine and originally dismissed as a marginal therapeutic experiment, has nevertheless emerged this year as a $1.7 billion revenue generator within the tightly regulated U.S. psychiatric drug market. The product’s trajectory from a cumbersome administration format that required specialized nasal delivery devices and extensive physician training to a marketable blockbuster reflects a regulatory environment that, while ostensibly cautious, has nonetheless permitted a rapid transition once commercial viability was demonstrated.

Despite the initial reluctance of insurers and the need for a risk‑evaluation and mitigation strategy that delayed reimbursement, the drug achieved widespread adoption as clinicians, pressured by the growing prevalence of treatment‑resistant depression and the scarcity of effective alternatives, increasingly prescribed the nasal spray in a manner that aligns with Johnson & Johnson’s broader strategy of monetising novel delivery systems. The resulting $1.7 billion in sales, reported in the most recent financial quarter, underscores not only the commercial allure of repurposing a controlled‑substance anesthetic for psychiatric use but also the institutional willingness to accommodate a product whose clinical benefits remain contested by a segment of the psychiatric community.

In effect, the Spravato saga illustrates how a pharmaceutical conglomerate can navigate and, when advantageous, exploit a convoluted approval pathway, turning a molecule once relegated to operating rooms into a lucrative outpatient therapy while simultaneously exposing the uneasy compromise between rigorous drug safety oversight and the profit‑driven imperatives that increasingly shape contemporary mental‑health treatment paradigms. Consequently, policymakers and clinicians alike are left to reconcile the apparent success of a drug that thrived under a system that balances patient need, regulatory caution, and corporate ambition, a balancing act that, given the present outcomes, appears more a testament to market resilience than to therapeutic innovation.

Published: May 1, 2026